Clinical Trial Goal
To find out:
- The highest dose of CIML-NK cells that's safe to give
- If the combination of atezolizumab and CIML-NK cells is safe and works well to treat AML that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 - 70 years old
- Have AML that has relapsed or is refractory
- Have a family member who is willing and able to be your donor
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Atezolizumab is a checkpoint inhibitor that targets PD-L1 on certain cells.
NK cells are a kind of immune cell that can attack cancer cells.
Before the CIML-NK cell infusion, you’ll get chemotherapy (chemo) with 2 standard drugs:
NK cells are a kind of immune cell that can attack cancer cells.
Before the CIML-NK cell infusion, you’ll get chemotherapy (chemo) with 2 standard drugs:
- Cyclophosphamide – Given as intravenous (IV) infusions 2 times
- Fludarabine – Given as IV infusions 2 times
Next, the CIML-NK cells are given to you through an IV infusion. The dose of cells you’ll get depends on when you start the trial and how safe it has been.
Then, you will get:
- Atezolizumab - Given as an IV infusion 1 time
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved CIML-NK cell therapy.
Locations
Sponsors
collaborator: Genentech, Inc., lead: Memorial Sloan Kettering Cancer Center
